The addressed point of care diagnostics market is a large segment in the total in vitro diagnostic market and accounts for approximately $11B per year, with an annual growth of 19%.

The PoC market is an important complementary driving force for the transition to personalised medicine, which is gaining considerable traction as all stakeholders regularly re-evaluate the optimal way to provide healthcare cost-effectively.

The innovative platform technologies developed in the PoC-ID project will support the strong trend to personal healthcare, consumer home-use of medical electronics, and bedside testing & monitoring with the objectives of cost reduction and improvement in quality of life.